Targeting Tumors Using Peptides.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Solid tumors present challenges for drug delivery due to dense stroma and high interstitial fluid pressure.
• Low molecular weight (Mw < 10 KDa) compounds offer advantages in tumor penetration over larger molecules like antibodies.
• Effective tumor targeting requires strategies that overcome the physical barriers within the tumor microenvironment.

Purpose of the Study:

• To review peptidic ligands (linear, cyclic, macrocyclic, cyclotidic) for targeting solid tumors.
• To discuss experimental and in silico methods for identifying and modifying tumor-targeting peptides.
• To present the current state-of-the-art in low Mw molecule-based tumor targeting and ligand discovery.

Main Methods:

• Experimental identification techniques, including phage display.
• Chemical modifications to enhance peptide properties.
• In silico identification of peptides and review of non-peptidic ligands in clinical stages.
• Focus on validated ligands targeting tumor vasculature, extracellular matrix, and tumor-associated macrophages.

Main Results:

• Peptidic ligands demonstrate potential for targeting various tumor compartments.
• Both experimental and computational approaches are valuable for discovering novel tumor-targeting ligands.
• Clinical progress and setbacks of therapeutic conjugates utilizing these ligands are analyzed.

Conclusions:

• Low molecular weight compounds, particularly peptides, are promising for enhanced solid tumor penetration.
• A comprehensive understanding of ligand identification and modification tools is crucial for advancing cancer therapy.
• Continued research into validated ligands and their conjugates is essential for improving clinical outcomes.